^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | taniraleucel (CYNK-001) (NK cell stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Celularity Announces Fast Track Designation by the FDA for our Natural Killer Cell Therapy CYNK-001 in the Treatment of Recurrent Glioblastoma Multiforme
Published date:
03/18/2021
Excerpt:
...Celularity Inc. (“Celularity”)...announced that the company has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-001, for the treatment of adults with recurrent glioblastoma multiforme (GBM).
